Checkpoint immunotherapy is enhanced when CD8+ T cells and T regulatory cells are "cut off.".

Published Date: 12 Jun 2024

The accepted approach to treating metastatic melanoma now involves checkpoint immunotherapy with PD-1 blockade. Although forty percent of patients respond well to this treatment, the other sixty percent experience resistance, which results in tumor regrowth.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot